Hu Yanghao, Zhang Yifei, He Jiali, Rao Huihuang, Zhang Duomi, Shen Zhisen, Zhou Chongchang
Department of Otorhinolaryngology Head and Neck Surgery, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, Zhejiang, China.
Health Science Center, Ningbo University, Ningbo, Zhejiang, China.
Front Immunol. 2025 Apr 28;16:1570333. doi: 10.3389/fimmu.2025.1570333. eCollection 2025.
Anoctamin 1 (ANO1), also known as TMEM16A, is a multifunctional protein that serves as a calcium-activated chloride channel (CaCC). It is ubiquitously expressed across various tissues, including epithelial cells, smooth muscle cells, and neurons, where it is integral to physiological processes such as epithelial secretion, smooth muscle contraction, neural conduction, and cell proliferation and migration. Dysregulation of ANO1 has been linked to the pathogenesis of numerous diseases. Extensive research has established its involvement in non-neoplastic conditions such as asthma, hypertension, and gastrointestinal (GI) dysfunction. Moreover, ANO1 has garnered significant attention for its role in the development and progression of cancers, including head and neck cancer, breast cancer, and lung cancer, where its overexpression correlates with increased tumor growth, metastasis, and poor prognosis. Additionally, ANO1 regulates multiple signaling pathways, including the epidermal growth factor receptor (EGFR) pathway, the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway, and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway, among others. These pathways are pivotal in regulating cell proliferation, migration, and invasion. Given its central role in these processes, ANO1 has emerged as a promising diagnostic biomarker and therapeutic target. Recent advancements in ANO1 research have highlighted its potential in disease diagnosis and treatment. Strategies targeting ANO1, such as small molecule modulators or gene-silencing techniques, have shown preclinical promise in both non-neoplastic and neoplastic diseases. This review explores the latest findings in ANO1 research, focusing on its mechanistic involvement in disease progression, its regulation, and its therapeutic potential. Modulating ANO1 activity may offer novel therapeutic strategies for effectively treating ANO1-associated diseases.
anoctamin 1（ANO1），也被称为TMEM16A，是一种多功能蛋白质，作为钙激活氯离子通道（CaCC）发挥作用。它在包括上皮细胞、平滑肌细胞和神经元在内的各种组织中普遍表达，在诸如上皮分泌、平滑肌收缩、神经传导以及细胞增殖和迁移等生理过程中不可或缺。ANO1的失调与多种疾病的发病机制有关。广泛的研究已证实其参与哮喘、高血压和胃肠（GI）功能障碍等非肿瘤性疾病。此外，ANO1因其在包括头颈癌、乳腺癌和肺癌在内的癌症发生和发展中的作用而备受关注，其过表达与肿瘤生长增加、转移和不良预后相关。此外，ANO1调节多种信号通路，包括表皮生长因子受体（EGFR）通路、丝裂原活化蛋白激酶（MAPK）/细胞外信号调节激酶（ERK）通路以及磷脂酰肌醇3激酶（PI3K）/蛋白激酶B（AKT）通路等。这些通路在调节细胞增殖、迁移和侵袭中起关键作用。鉴于其在这些过程中的核心作用，ANO1已成为一个有前景的诊断生物标志物和治疗靶点。ANO1研究的最新进展突出了其在疾病诊断和治疗中的潜力。针对ANO1的策略，如小分子调节剂或基因沉默技术，在非肿瘤性和肿瘤性疾病的临床前研究中均显示出前景。本综述探讨了ANO1研究的最新发现，重点关注其在疾病进展中的机制性参与、调节及其治疗潜力。调节ANO1活性可能为有效治疗与ANO1相关的疾病提供新的治疗策略。
Zotero 插件
